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A u t h o r P r o o f
part of CNS tumors are the most common solid tumors of childhood [1] . Although treatment advances have improved survival for some pediatric CNS diseases, there unfortunately remains a group of tumors associated with significantly poorer prognosis. Among these are high-grade gliomas (HGG), which, despite aggressive management, usually recur and are associated with 5-year survival outcomes between 15-35% [2] . Diffuse intrinsic pontine glioma (DIPG), a highly malignant brainstem tumor with median survival of less than 1 year [3] , remains a constant therapeutic challenge. High-risk metastatic medulloblastoma with cerebrospinal fluid dissemination at presentation is associated with 5-year survival rates between 40-70% despite intensive treatment regimens [4] . In addition, rare malignancies, such as atypical teratoid rhabdoid tumors, although often demonstrating response to chemotherapy, are associated with early relapse and a median survival of only 17 months [5] . Oncolytic virotherapy, which uses viruses to selectively infect and destroy cancer cells [6] , offers a novel treatment approach for poor prognosis pediatric CNS tumors. While there is extensive literature on oncolytic virotherapy for adult brain malignancies, such as HGG, work on pediatric CNS tumors is currently only just gathering steam. With no open clinical trials focused on oncolytic virotherapy in pediatric CNS tumors we can currently only draw upon available preclinical models, alongside adult and limited pediatric clinical data, to progress the exciting future potential of this treatment modality.
The majority of preclinical studies of oncolytic virotherapy for pediatric CNS tumors evaluate efficacy in medulloblastoma. Over 15 years ago Lasner et al. published that herpes simplex virus (HSV) variant 1716 could infect and destroy D283 medulloblastoma cells and demonstrated that intratumoral injection of the virus into D283 tumor-bearing mice conferred a statistically significant increase in survival compared with control murine models [7] . Pyles et [9] . Furthermore, a significant survival advantage was shown following single and multiple intratumoral injection of reovirus into DAOY cell orthotopic mouse models over controls, with multiple administrations also reducing spinal and leptomeningeal metastases [9] . More recently, Studebaker et al. have also demonstrated the potential for oncolytic virotherapy in treatment of disseminated disease. The authors showed that medulloblastoma cells were susceptible to killing with recombinant measles virus [10] . They then went on to generate and characterize a mouse model of disseminated disease that, when treated with intraventricular measles virus, significantly increased survival of animals when compared with controls treated with inactivated virus [11] . Other publications have demonstrated that medulloblastoma is sensitive to myxoma [12] and seneca valley virus (SVV) infection [13] . Interestingly, Yu et al. showed that a single tail vein injection of SVV-001 in immunodeficient orthotopic xenograft mouse models of medulloblastoma resulted in widespread infection of the xenografts, demonstrating that virus penetration through the blood-brain barrier is possible [13] . This is extremely promising in the context of the clinical applicability of oncolytic virotherapy and the potential for intravenous systemic delivery.
Unlike its adult counterpart, only a small amount of research has focused on oncolytic virotherapy for pediatric HGG, although published work has evaluated a role for HSV and SVV. Freidman et al. have shown that a pediatric cerebellar glioblastoma xenograft DM456 contains tumor and cancer stem cells that are more sensitive to killing by a range of modified HSVs than adult glioma xenografts [14] . One such HSV IL-12 producing virus (M002), which demonstrated killing in DM456, is thought to be particularly promising as a potential clinical therapeutic agent [15] . This is a result of its demonstrated safety in primate toxicity studies and its superior anti-tumor activity in murine models over HSV G207 [16] , which has previously been used in adult glioblastoma clinical trials [17] . An adult clinical trial is in development and, if safe, it is hoped that this may progress to a pediatric trial [15] . SVV (NTX-010) was tested on a range of pediatric tumors including the brain tumors glioblastoma, medulloblastoma and ependymoma [18] . Although the most consistent cytotoxic effects were seen in neuroblastoma and rhabdomyosarcoma lines, some objective response was also seen in the glioma lines: NTX-010 was not effective on the medulloblastoma and ependymoma lines in this study [18] . Further preclinical studies evaluating the efficacy and safety of existing and emerging oncolytic viruses in pediatric HGG are required. In addition, the role of oncolytic viruses for malignancies such as atypical teratoid rhabdoid tumors and DIPG remains to be explored.
Although clinical testing of oncolytic virotherapy for pediatric CNS tumors is in its infancy, there are already a handful of encouraging reports in the literature that lay the foundations for future clinical work. Csatary et al. report three pediatric patients (18 months to 12 years at diagnosis) with malignant grade III/IV glioma who, following the failure of conventional treatment, went on to receive regular intravenous therapy with the Newcastle disease virus MTH-68/H for several years. At time of publication, all three patients still continued with maintenance virus therapy and demonstrated between 7-9 years survival with good quality of life [19] . Furthermore, a case report describes a 12-year-old boy with chemotherapy-and radiotherapy-resistant grade III anaplastic astrocytoma, who received intravenous and inhaled MTH-68/H alongside valproic acid. This led to dramatic regression of his original tumor; however, it did not repress the growth of two further tumors, which ultimately led to his death [20] . Encouragingly, Newcastle disease virus antigen and constituents were found in tumor tissue confirming successful systemic delivery of the virus to the tumor and demonstrating the virus's ability to infect and replicate in pediatric human cancer cells [20] . Finally, one pediatric patient, aged 11 years, was recruited into a Phase I/II trial of intravenous NVD-HUJ for recurrent glioblastoma, which overall demonstrated good tolerability, no major side effects and a complete tumor response in one other adult patient [21] . Promising results have been demonstrated in adults in terms of safety, tolerability and multiple-dose delivery data in Phase I and II clinical trials using a range of different viruses for treatment of malignant gliomas [6, 17] . Recently, a handful of oncolytic virus trials for pediatric patients with non-CNS solid tumors has been developed [22] , which will begin to answer questions regarding dosing, safety and efficacy of virotherapy in children. The next step for the pediatric field is to amalgamate the knowledge gained from preclinical studies together with adult and pediatric clinical observations, in order to decide which viruses to take forward to clinical trials for pediatric CNS tumors.
There are many questions that must be answered before oncolytic virus therapy reaches its full potential for pediatric patients with CNS disease. First and foremost, safety issues must be addressed. One issue that relates solely to pediatric oncology and where minimal information is known, is the effect of oncolytic viruses on the developing brain and subsequent neurodevelopmental outcomes. Although a murine study showed that intracerebral injection of modified herpes virus G207 did not adversely affect cognitive or behavioral development in young mice when compared with saline-treated controls, some mice in the treatment group developed ventriculomegaly [23] . Although the study had limitations and the authors admitted concerns that the delivery method of the virus itself may have resulted in such findings, it does raise the possibility that hydrocephalus may be a potential problem for young children receiving intracranial virotherapy and that any subsequent trials should involve monitoring for this adverse effect [23] . Furthermore, tumor location must be considered when assessing safety. In particular, brainstem tumors, such as DIPG, may be of particular concern, as local pressure generated from immune and inflammatory responses alongside viral replication may cause critical, if not fatal consequences [24] . One obvious concern for pediatricians would be the risk of uncontrollable viral replication, resulting in encephalitis and subsequent neurodevelopmental sequelae. This risk could be overcome by ensuring availability of effective antiviral treatments if significant toxicity does occur. Effective administration and delivery of the virus must also be considered. Intratumoral injection limits the number of opportunities for treatment in children, whereas systemic delivery may be fraught with problems in effectively penetrating the blood-brain barrier and overcoming the potential for neutralization of the virus by the patient's immune system before it can access its tumor target. Further research and clinical experience is required in order to optimize virus delivery to pediatric, as well as adult, intracranial tumors.
Additional questions relate to the immunotherapeutic properties of oncolytic viruses. There is clearly a fine balance between minimizing destruction of administered virus by the host immune system, while enhancing the immune system's response to kill and ablate virus-infected cancer cells [6, 25] . One avenue of research is currently focused on developing cellular carriers that deliver viruses to tumors while hiding them from the neutralizing effects of the immune system [6] . Furthermore, viruses can be modified to express tumor antigens, so that when they are appropriately delivered to the immune system the anti-tumor immune response is enhanced [6] . Specific to pediatrics is the fact that young children may not yet have been exposed to naturally occurring viruses that may subsequently be used for virotherapy, and, therefore, will not have built up specific antiviral immunity [24] . Whether or not this will enhance the efficacy and/or toxicity of systemic oncolytic virotherapy in the younger age group remains to be determined. Finally, the financial and logistical difficulties in orchestrating clinical trials with adequate power in relatively rare childhood conditions must be considered, as well as the time lag to interpretation of trial results while newer and more promising viruses are developed in this rapidly evolving field.
Despite recent advances in the field of pediatric neurooncology, morbidity and mortality for this patient group remains high and novel treatment avenues for unfavorable outcome pediatric CNS tumors are desperately required [4] . Preclinical studies have demonstrated the potential for oncolytic virotherapy as a treatment paradigm for these childhood tumors, although very limited, clinical observations in children have shown promise. The next step for the field is the development and delivery of Phase I trials for pediatric CNS tumors evaluating a range of potential oncolytic viruses. This will allow the opportunity to begin to answer a range of important clinical questions. Future research will concentrate on optimizing virus delivery, modulating the role of the child's immune system to prevent viral elimination, 
